Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), published in January 2023, was modified according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with oncogene-addicted mNSCLC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with oncogene-addicted mNSCLC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Korean Society for Medical Oncology (KSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with oncogene-addicted mNSCLC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, while respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between the different regions of Asia.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2024-11-29
DOI
https://doi.org/10.1016/j.esmoop.2024.103996
Citations
16
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
6.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

M. Thiagarajan, Marcelo Severino Bulauitan Imasa, Mark John D Sabando, J.O. Park et al.
16 citations
ESMO Open
Lung Cancer Treatments and Mutations
6.70
article

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

M. Thiagarajan, Marcelo Severino Bulauitan Imasa, Mark John D Sabando, J.O. Park, George E. Pentheroudakis, Hidenori Mizugaki, Caicun Zhou, Vanita Noronha, Jessica Menis, K. Prabhash, H. Hayashi, J.B. Ahn, Hye Ryun Kim, T.M. Kim, Yi Lin Teh, Takayuki Yoshino, Solange Peters, Dong‐Gun Lee, Se‐Hoon Lee, Elizabeth Smyth, Jie Yang, Thanyanan Reungwetwattana, S. Popat, Li Zhang, Sehhoon Park, C.-E. Wu, Sri Kurniawati, Virote Sriuranpong, Yvonne Ang, Mira Yulianti
article en
16 citations

Abstract

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), published in January 2023, was modified according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with oncogene-addicted mNSCLC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with oncogene-addicted mNSCLC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Korean Society for Medical Oncology (KSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with oncogene-addicted mNSCLC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, while respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between the different regions of Asia.

ESMO OpenVol. 9(12)
Tongji University (CN), University of Verona (IT), Sun Yat-sen University (CN), Chulalongkorn University (TH), National Taiwan University (TW), Chang Gung University (TW), Yonsei University (KR), Homi Bhabha National Institute (IN), Lung Center of the Philippines (PH), Hospital Kuala Lumpur (MY), European Society for Medical Oncology (CH), Oxford Health NHS Foundation Trust (GB), Samsung Medical Center (KR), King Chulalongkorn Memorial Hospital (TH), Centre Hospitalier Universitaire Vaudois (CH), Seoul National University Hospital (KR), University of Indonesia (ID), Bicol University (PH), University of Malaya (MY), University of Oxford (GB), University of Santo Tomas–Legazpi (PH), National University Cancer Institute, Singapore (SG), Linkou Chang Gung Memorial Hospital (TW), Shanghai Pulmonary Hospital (CN), National Cancer Centre Singapore (SG), Ramathibodi Hospital (TH), National Cancer Center Hospital East (JP), Sun Yat-sen University Cancer Center (CN), Dharmais Cancer Hospital (ID), Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (ID), Sungkyunkwan University (KR), Kindai University (JP)
Mesothelioma Applied Research Foundation, Eli Lilly and Company, AstraZeneca, GlaxoSmithKline, Ariad Pharmaceuticals, Celgene, European Society for Medical Oncology, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 2%
Lung Cancer Treatments and Mutations
6.70
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.